Ideaya Biosciences Inc(IDYA) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -1.94 | Insider Own | 6.64% | Shs Outstand | 96.4M | Perf Week | -2.75% |
| Market Cap | 3.17B | Forward P/E | - | EPS next Y | 8.26% | Insider Trans | -0.56% | Shs Float | 90.1M | Perf Month | -10.38% |
| Enterprise Value | 2.37B | PEG | - | EPS next Q | -1.17 | Inst Own | 101.83% | Short Float | 10.19% | Perf Quarter | -9.07% |
| Income | -0.18B | P/S | 13.55 | EPS this Y | -259.79% | Inst Trans | 6.71% | Short Ratio | 11.56 | Perf Half Y | 11.53% |
| Sales | 0.23B | P/B | 2.64 | EPS next 5Y | - | ROA | -14.89% | Short Interest | 9.18M | Perf YTD | -4.89% |
| Book/sh | 12.44 | P/C | 3.83 | EPS past 3/5Y | 3.17% 1.64% | ROE | -16.22% | 52W High | -22.96% ($42.68) | Perf Year | 12.68% |
| Cash/sh | 8.59 | P/FCF | - | Sales past 3/5Y | 62.54% 62.11% | ROIC | -14.26% | 52W Low | 22.64% ($26.81) | Perf 3Y | 21.51% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 49.14% | Gross Margin | 98.08% | Volatility(W/M) | 5.01% 4.26% | Perf 5Y | 48.78% |
| Dividend TTM | - | EV/Sales | 10.14 | Sales Y/Y TTM | 3244.67% | Oper. Margin | -92.66% | ATR (14) | 1.49 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 10.45 | EPS Q/Q | -39.46% | Profit Margin | -74.75% | RSI (14) | 35.53 | Recom | 1.12 |
| Dividend Gr. 3/5Y | - | Current Ratio | 10.45 | Sales Q/Q | - | SMA20 | -7.87% ($35.69) | Beta | 0.06 | Target Price | $52.38 |
| Payout | - | Debt/Eq | 0.02 | Earnings | 2026/8/4 | SMA50 | -12.66% ($37.65) | Rel Volume | 1.5 | Prev Close | $34.71 |
| Employees | 145 | LT Debt/Eq | 0.02 | EPS/Sales Surpr. | -15.46% 10.44% | SMA200 | -3.54% ($34.09) | Avg Volume(3M) | 0.79M | Price | $32.88 |
| IPO | 2019/5/23 | Option/Short | Yes/Yes | Trades | 10214 | Volume | 1,188,227 | Change | -5.27% |
A US-based clinical-stage biotech company developing precision oncology therapeutics using synthetic lethality mechanisms. The company develops small-molecule compounds and protein degraders that target specific genetic vulnerabilities in cancer cells, pursuing entry into the precision oncology market through a differentiated strategy focused on less competitive target areas and collaborations with major pharmaceutical companies.
Over the past 1 year, roughly in the middle
23% below its 1-year high.
Traded more than usual. That is 150% of its average volume.
IDYA has a sound balance sheet but weak earning power
Of every $100 in sales, $92.66 is lost.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -259.8% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $1,355. Peers typically go for $1,575.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +48.8%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 101.8%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #67 of 594 in the industry
Based on market cap of $3B.
CELC#66 Celcuity Inc $3B PER - IDYA#67 Ideaya Biosciences Inc $3B PER - 
PBLS#68 Parabilis Medicines Inc $3B PER - 
VKTX#69 Viking Therapeutics Inc $3B PER - 
TLX#70 Telix Pharmaceuticals Ltd ADR $3B PER 96.2 
FAQ
What kind of company is IDYA?
IDYA belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of IDYA?
The market cap of IDYA is approximately $3.2B, ranking 1,687 within its sector.
What is the 52-week high and low for IDYA?
IDYA has recorded a 52-week high of $42.68 and a low of $26.81.
